Repros Therapeutics Inc (NASDAQ: RPRX) stock gained 3.4%
to $12.64 after the company this week announced that it now plans to provide
clinical results from the first pivotal study, ZA-301, of Androxal, in the
treatment of secondary hypogonadism in Q3 2013 instead of Q2 2013. Share volume
was 97,700, compared to an all-day average of 110,300
